Back to results
US 11,767,310 B2Granted
Nicotinamide RIPK1 inhibitors
AssigneeAbbVie Inc.
InventorsKevin Patrick Cusack, Michael Zeller Hoemann, David Andrew Kinsman, Sami Osman, James Patrick Stambuli, Maria Anastasia Argiriadi, Ciaran O'Reilly, Hannah Dexter, Euan Fordyce, Steve St. Gallay
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. Also provided are methods of treating Ulcerative Colitis using a compound of Formula (I).
Claims8
A compound represented by the following structure:
- or a pharmaceutically acceptable salt thereof.
A compound represented by the following structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.